Northwest Biotherapeutics (NWBO) Cash from Investing Activities (2010 - 2026)
Northwest Biotherapeutics (NWBO) posted quarterly Cash from Investing Activities of -$129000.0 for Q1 2026, down 38.71% year-over-year from -$210473.7 in Q1 2025, and up 85.75% quarter-over-quarter from -$905000.0 in Q4 2025.
Powered by 
Analysis
Northwest Biotherapeutics (NWBO) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Northwest Biotherapeutics' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$129000.0 for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 38.71% year-over-year to -$129000.0; the TTM figure through Mar 2026 stood at -$1.9 million (down 113.25% YoY), while the FY2025 annual figure was -$1.8 million, down 78.99% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$129000.0, up from -$905000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was -$58000.0 in Q1 2022, with the low at -$2.2 million in Q4 2022.
- The 5-year median for Cash from Investing Activities is -$408000.0 (2022), against an average of -$546882.4.
- The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities surged 89.74% in 2022, then plunged 2198.28% in 2023.
- Northwest Biotherapeutics' Cash from Investing Activities stood at -$2.2 million in 2022, then soared by 80.65% to -$418000.0 in 2023, then surged by 81.34% to -$78000.0 in 2024, then slumped by 1060.26% to -$905000.0 in 2025, then surged by 85.75% to -$129000.0 in 2026.
- Business Quant data shows NWBO's Cash from Investing Activities at -$129000.0 in Q1 2026, -$905000.0 in Q4 2025, and -$513000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Northwest Biotherapeutics | 278.23 Mn | 277.63 Mn | - | -198,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -198,000.00 |
| Mar 31, 2026 | -129,000.00 |
| Dec 31, 2025 | -905,000.00 |
| Sep 30, 2025 | -513,000.00 |
| Jun 30, 2025 | -304,000.00 |
| Mar 31, 2025 | -93,000.00 |
| Dec 31, 2024 | -78,000.00 |
| Sep 30, 2024 | -176,000.00 |
| Jun 30, 2024 | -521,000.00 |
| Mar 31, 2024 | -239,000.00 |
| Dec 31, 2023 | -418,000.00 |
| Sep 30, 2023 | -437,000.00 |
| Jun 30, 2023 | -1.25 Mn |
| Mar 31, 2023 | -1.33 Mn |
| Dec 31, 2022 | -2.16 Mn |
| Sep 30, 2022 | -276,000.00 |
| Jun 30, 2022 | -408,000.00 |
| Mar 31, 2022 | -58,000.00 |
| Dec 31, 2021 | -1.55 Mn |
| Sep 30, 2021 | -2.69 Mn |